


TT-OAD2 free base

Chemical Properties

CAS No. :	1246826-07-2
Formula:	C50H47Cl2N3O6
Molecular Weight:	856.83
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM.
Targets(IC50)	Others,Glucagon Receptor
In vitro	TT-OAD2, at concentrations ranging from 0 to 10 μM, suppresses GLP-1- and oxyntomodulin-induced responses—including cAMP, calcium, pERK1/2, and β-arrestin—in a dose-dependent manner within HEK293A cells.
In vivo	TT-OAD2 treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice.

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1671 mL	5.8355 mL	11.6709 mL
5 mM	0.2334 mL	1.1671 mL	2.3342 mL
10 mM	0.1167 mL	0.5835 mL	1.1671 mL
50 mM	0.0233 mL	0.1167 mL	0.2334 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436.
Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481